Dr. Agarwal's Health Care Share Price Today | Stock Price & Dr. Agarwal's Health Care Share Screener
As of November 19, 2026, the live Dr. Agarwal's Health Care share price (NSE: AGARWALEYE) is ₹553.10 on NSE and ₹554.90 on BSE, up 0.66% from the previous close, with shares trading between ₹544.70 and ₹558.50 in today's trading session, and a 52-week range of ₹406.55–₹560.70. Track AGARWALEYE market cap trends to gauge the company's total market size. Use the Dr. Agarwal's Health Care stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Dr. Agarwal's Health Care opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹665 and net income of ₹57, with EBITDA of ₹186, an operating margin of 27.0% and a profit margin of 8.6%.
Dr. Agarwal's Health Care Share Price Chart
Track the current stock price of Dr. Agarwal's Health Care with an interactive chart. Analyse AGARWALEYE share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Dr. Agarwal's Health Care stock quote in one place.
The quote of ₹553.10 sits between the 52-week low of ₹406.55 and the 52-week high of ₹560.70, and the latest session moved 0.66% from the previous close.
Dr. Agarwal's Health Care Company Profile - Fundamental Screener
Screen Dr. Agarwal's Health Care company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for AGARWALEYE shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Healthcare Services industry, and it trades under ISIN INE943P01029.
Company Details
Classification
Identifiers and Leadership
Dr. Agarwal's Health Care Balance Sheet Screener
Screen AGARWALEYE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹3,942, up from ₹3,672 in 2025.
Latest statistics put total assets at ₹3,942 and shareholder funds at ₹2,120, with a leverage ratio of 0.52.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Assets |
|||||||
| Total Assets | 3,942 | 3,672 | 2,753 | 1,825 | 1,026 | 787 | 752 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 2,870 | 2,523 | 1,746 | 1,293 | 702 | 575 | 551 |
Liabilities |
|||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1,361 | 1,267 | 974 | 865 | 586 | 438 | 339 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
|||||||
| Total Equity | 2,120 | 1,927 | 1,380 | 659 | 234 | 199 | 267 |
| Share Capital | 32 | 32 | 9 | 8 | 7 | 7 | 7 |
| Reserves & Surplus | 1,993 | 1,835 | 1,330 | 622 | 206 | 177 | 242 |
Dr. Agarwal's Health Care Income Statement Screener - Profit & Revenue Analysis
Screen Dr. Agarwal's Health Care income statement and profit fundamentals. Analyze AGARWALEYE quarterly results. Dr. Agarwal's Health Care reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Sept, revenue was ₹665 and net profit was ₹57, equal to earnings per unit of ₹1.65, at an operating margin of 27%.
In that period expenses were ₹480, interest cost ₹23 and tax ₹23. The next period listed, 2026-Jun, shows revenue of ₹620 and net profit of ₹55.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | ||||||||||||
| Revenue | 665 | 620 | 578 | 540 | 507 | 501 | 476 | 443 | 429 | 410 | 369 | 345 |
| Expenses | 480 | 444 | 403 | 386 | 363 | 360 | 332 | 316 | 310 | 300 | 241 | 244 |
Operating Costs and Margins | ||||||||||||
| EBITDA | 186 | 177 | 175 | 155 | 144 | 141 | 144 | 128 | 119 | 110 | 128 | 101 |
| Operating Profit % | 27.00% | 28.00% | 29.00% | 27.00% | 27.00% | 26.00% | 28.00% | 27.00% | 26.00% | 26.00% | 31.00% | 27.00% |
| Depreciation | 83 | 78 | 77 | 69 | 68 | 63 | 60 | 58 | 57 | 56 | 47 | 43 |
| Interest | 23 | 23 | 22 | 21 | 23 | 25 | 25 | 28 | 28 | 27 | 27 | 22 |
Profit and Earnings | ||||||||||||
| Profit Before Tax | 80 | 75 | 77 | 65 | 54 | 54 | 59 | 41 | 33 | 27 | 54 | 36 |
| Tax | 23 | 20 | 27 | 21 | 17 | 16 | 16 | 13 | 12 | 9 | 13 | 13 |
| Net Profit | 57 | 55 | 50 | 44 | 37 | 38 | 43 | 28 | 21 | 18 | 41 | 23 |
| EPS | 1.65 | 1.55 | 1.25 | 1.07 | 1.07 | 0.95 | 1.04 | 0.73 | 0.45 | 0.43 | 1.39 | 1.94 |
Dr. Agarwal's Health Care Cash Flow Screener - Liquidity Fundamentals
Screen AGARWALEYE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹519, and net cash flow was an outflow of ₹10.
Over the same period, investing activities used ₹309 and financing activities used ₹220.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | |||||||
| Operating Activities | 519 | 357 | 346 | 233 | 164 | 99 | 103 |
| Investing Activities | -309 | -750 | -914 | -509 | -155 | -46 | -85 |
Financing and Net Cash | |||||||
| Financing Activities | -220 | 382 | 553 | 303 | 35 | -37 | -74 |
| Net Cash Flow | -10 | -11 | -15 | 27 | 44 | 17 | -56 |
Dr. Agarwal's Health Care Shareholding Pattern Screener
See Dr. Agarwal's Health Care shareholding pattern with promoter, FII, and DII holdings. Check Dr. Agarwal's Health Care promoter holding and ownership changes for AGARWALEYE on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 32.36%, foreign institutions 57.94%, domestic institutions 7.83% and the public 1.68%, spread across 43,538 shareholders.
The shareholder count was 43,538 in 2026-Mar, compared with 42,492 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Jan | 2025-Feb | 2025-Mar | 2025-Jun | 2025-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 32.36% | 32.34% | 32.33% | 37.73% | 32.45% | 32.45% | 32.42% | 32.42% |
Institutional Investors | ||||||||
| FII Holding | 57.94% | 57.96% | 49.56% | 0.00% | 56.97% | 60.62% | 59.26% | 58.13% |
| DII Holding | 7.83% | 7.72% | 15.87% | 0.00% | 5.10% | 5.21% | 6.44% | 7.92% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 1.68% | 1.81% | 1.82% | 0.00% | 4.79% | 1.61% | 1.74% | 1.41% |
| Other Holding | 0.19% | 0.17% | 0.41% | 62.27% | 0.69% | 0.11% | 0.14% | 0.11% |
| Shareholder Count | 43,538 | 42,492 | 42,055 | 43 | 217,289 | 68,696 | 63,021 | 48,168 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Dr. Agarwal's Health Care. Dr. Agarwal's Health Care dividend yield can be compared with peers and other stocks in the market.
Dr. Agarwal's Health Care Stock Index Membership - Nifty & Sensex
See which indices include Dr. Agarwal's Health Care stock. Check AGARWALEYE index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 2 indices, including BSE INDEX BSEIPO.
Among the benchmarks tracked are BSE INDEX BSEIPO, NIFTY IPO.
Complete Index List
Dr. Agarwal's Health Care Market Events Screener - Corporate Actions
Get Dr. Agarwal's Health Care corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Dr. Agarwal's Health Care stock events that may affect AGARWALEYE share price, along with derivatives, futures and options activity and sector gainers.
11 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 5, 2026, with a record date of November 5, 2026.
It is followed by Annual General Meeting dated September 21, 2026 and Quarterly Result Announcement dated August 4, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-05 | 2026-11-05 | Quarterly Result Announcement | NA | 11.78% |
| 2026-09-21 | 2026-09-21 | Annual General Meeting | NA | 0.63% |
| 2026-08-04 | 2026-08-04 | Quarterly Result Announcement | NA | 1.63% |
| 2026-07-02 | 2026-07-02 | Extraordinary General Meeting | NA | -3.02% |
| 2026-05-21 | 2026-05-21 | Quarterly Result Announcement | NA | 2.95% |
| 2026-02-03 | 2026-02-03 | Quarterly Result Announcement | NA | -1.33% |
| 2025-10-30 | 2025-10-30 | Quarterly Result Announcement | NA | -5.93% |
| 2025-09-24 | 2025-09-24 | Annual General Meeting | NA | 6.16% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | 0.07% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | -6.56% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | 11.55% |
Dr. Agarwal's Health Care Competitors Screener - Peer Stocks Comparison
Screen AGARWALEYE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Apollo Hospitals | 125,272 | 53.90 | 25,420 | 15.58% | 2,003 | 61.89 |
| Max Healthcare Institute | 100,339 | 71.20 | 8,536 | 18.82% | 1,442 | 76.17 |
| Manipal Health Enterprises | 92,333 | 104.20 | 10,521 | 25.80% | 917 | 60.80 |
| Aster DM Quality Care | 64,325 | 116.10 | 4,769 | 11.25% | 427 | 57.55 |
| Fortis Healthcare | 60,910 | 57.00 | 9,179 | 16.93% | 1,064 | 57.30 |
| Narayana Hrudayalaya | 38,984 | 45.00 | 7,996 | 43.43% | 811 | 61.49 |
| Global Health | 38,830 | 62.80 | 4,509 | 19.56% | 554 | 64.64 |
| Dr. Lal Path Labs | 33,237 | 57.20 | 2,864 | 12.11% | 510 | 54.28 |
| Krishna Institute of Medical Sciences | 32,269 | 163.00 | 3,931 | 28.16% | 242 | 66.73 |
| Syngene International | 17,533 | 95.70 | 3,809 | 2.56% | 317 | 61.78 |
Dr. Agarwal's Health Care Company Announcements - News & Reports Screener
Screen AGARWALEYE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 18, 2026.
The next most recent announcements are dated November 13, 2026 and November 5, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-18 | Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements | - |
| 2026-11-13 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-11-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-11-05 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-11-05 | Corrigendum To Outcome Of The Board Meeting Held On November 05 2026 | - |
| 2026-11-05 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-11-05 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-11-05 | Consolidated And Standalone Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30 2026 | - |
| 2026-11-05 | Board Meeting Outcome for Consolidated And Standalone Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026 And Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-10-23 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-23 | Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended September 30 2026 | - |
| 2026-10-20 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-10-20 | Fixation Of Record Date W.R.T. The Scheme Of Amalgamation Between Dr. Agarwals Eye Hospital Limited And Dr. Agarwals Health Care Limited | - |
| 2026-10-20 | Board Meeting Outcome for Material Update On The Scheme Of Amalgamation Between Dr. Agarwals Eye Hospital Limited And Dr. Agarwals Health Care Limited And Their Respective Shareholders And Creditors | - |
| 2026-10-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-05 | Announcement under Regulation 30 (LODR)-Scheme of Arrangement | - |
| 2026-09-29 | Announcement under Regulation 30 (LODR)-Updates on Acquisition | - |
| 2026-09-29 | Announcement under Regulation 30 (LODR)-Cessation | - |
| 2026-09-28 | Closure of Trading Window | - |
| 2026-09-21 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹553.10, within a 52-week range of ₹406.55 to ₹560.70. The P/E ratio is 85.00 and the P/B ratio is 7.81, with earnings per unit of ₹4.21. Market capitalisation stands at ₹17,117.83 Cr. The company operates in the Healthcare sector, in the Healthcare Services industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 7 balance sheet periods, 12 income statement periods, 7 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.